These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 6947406)

  • 41. Cefamandole: pharmacokinetics and therapeutic evaluation in urology.
    Zinati AH; Naber KG
    Arzneimittelforschung; 1980; 30(5):839-42. PubMed ID: 7190432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis.
    Tomino Y; Fukui M; Hamada C; Inoue S; Osada S
    Arzneimittelforschung; 1998 Aug; 48(8):862-7. PubMed ID: 9748717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of azlocillin in persons with normal and impaired renal functions.
    Fiegel P; Becker K
    Antimicrob Agents Chemother; 1978 Sep; 14(3):288-91. PubMed ID: 708008
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of the new broad spectrum penicillin CP-33994-2.
    Bergan T; Brodwall EK; Orjavik O
    Arzneimittelforschung; 1980; 30(7):1144-7. PubMed ID: 7191297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elimination of azlocillin in patients with biliary t-tube drainage.
    Gundert-Remy U; Weber E
    Eur J Clin Pharmacol; 1982; 22(5):435-9. PubMed ID: 7117356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. International clinical experience with azlocillin.
    Schacht P; Arcieri G; Bruck H; Griffith E; Hullman R; Tettenborn D
    J Antimicrob Chemother; 1983 May; 11 Suppl B():215-22. PubMed ID: 6619030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of urinary tract infections in children with chronic renal failure on peritoneal dialysis].
    Szczepańska M; Szprynger K; Adamczyk P
    Pol Merkur Lekarski; 2004 Mar; 16(93):223-7. PubMed ID: 15190595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis.
    Zilch O; Vos PF; Oey PL; Cramer MJ; Ligtenberg G; Koomans HA; Blankestijn PJ
    J Hypertens; 2007 Jun; 25(6):1285-9. PubMed ID: 17563543
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)].
    Kiechel JR; Lavene D; Gurret M; Coustenoble J; Petrover M; Godin M; Fillastre JP
    Nephrologie; 1980; 1(2):73-81. PubMed ID: 7029332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of azlocillin after discontinuous intravenous administration of high dose.
    Naber KG; Adam D
    J Antimicrob Chemother; 1983 May; 11 Suppl B():115-20. PubMed ID: 6619021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
    Dager WE; King JH
    Ann Pharmacother; 2006 Jan; 40(1):9-14. PubMed ID: 16332944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacokinetics of dibekacin in patients with chronic renal impairment].
    Viotte G; Leroy A; Godin M; Fillastre JP
    Nouv Presse Med; 1982 Nov; 11(46):3414-8. PubMed ID: 7155849
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Morphological and biochemical features of fungi isolated from patients with renal failure].
    Drozdowska A
    Wiad Parazytol; 2007; 53(2):145-8. PubMed ID: 17912812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The pharmacokinetics of azlocillin after single and multiple intravenous injections during the third trimester].
    Voigt R; Weidt I; Schröder S; Brandstädt A; Peiker G
    Zentralbl Gynakol; 1988; 110(15):944-8. PubMed ID: 3055753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic studies of azlocillin, mezlocillin, cephalothin and sisomicin in rabbits.
    Dzierzanowska D; Patzer J; Jeljaszewicz J
    Infection; 1982; 10 Suppl 3():S217-20. PubMed ID: 6218118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mezlocillin the treatment of urinary tract infections.
    de Almeida TR; Prieto P; de Carvalho JA; Trabulsi LR
    Arzneimittelforschung; 1979; 29(12a):1992-4. PubMed ID: 543910
    [No Abstract]   [Full Text] [Related]  

  • 58. The safety and tolerance of azlocillin.
    Parry MF
    Arzneimittelforschung; 1985; 35(8):1292-4. PubMed ID: 4074446
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection.
    Roth S; Naber K; Scheer M; Gruenwaldt G; Lange H
    Eur J Clin Pharmacol; 1976 Sep; 10(5):357-65. PubMed ID: 789084
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation.
    Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Manini P; Andreoli R; Cabassi A
    Nephrol Dial Transplant; 2006 May; 21(5):1402-6. PubMed ID: 16504979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.